Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
To establish the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10
in pre-manifest participants carrying the CAGn expansion for Huntington's Disease (HD).
Phase:
Phase 2
Details
Lead Sponsor:
Huntington Study Group Johns Hopkins University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)